HIGHLIGHTS
- who: For correspondence et al. from the National Medical University of the have published the research: u0423u0414u041a: 618.19-006.6-085, in the Journal: (JOURNAL)
- what: In this research effectiveness, safety, and expenses during the treatment of CLL were compared according to the following regimens:. obinutuzumab + chlorambucil (u041e+Clb, GClb regimen);. rituximab + chlorambucil (R+Clb regimen).
- how: The research was conducted in 25 centers of 8 countries. When building the model the following assumptions were made the patients which were in PFS condition would not receive therapy in the event of disease . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.